GET DAILY SIGNALSBiodesix (BDSX) Stock Falls -29% Over 30 Days: Profit-Taking or Deeper Reset?
Key Takeaways
- BDSX has fallen roughly 29% over the past 30 days, retreating from about $29.10 to near $20.79 after peaking at a 52-week high of $31.97 in late September.
- The pullback reflects profit-taking and a sharp valuation reset following a rapid multi-week advance, rather than a specific negative company announcement.
- Operating fundamentals held firm: Biodesix reaffirmed full-year 2026 revenue guidance of $108–$114 million and reported 34% year-over-year revenue growth in Q2 2026.
- Wall Street sentiment stayed constructive, with multiple analysts raising price targets into October and a consensus "Strong Buy" rating near a $39 average target.
- Over the trailing quarter, the stock round-tripped from the low $20s to near $32 and back, leaving it roughly flat versus three months ago.
Biodesix (BDSX) Business Snapshot
Biodesix, Inc. is a diagnostic solutions company focused on lung disease. Its flagship Nodify Lung platform — including the Nodify XL2 and Nodify CDT tests — uses blood-based proteomic analysis to help physicians assess whether suspicious lung nodules are more likely to be malignant or benign. The company also markets IQLung tests such as GeneStrat and VeriStrat, which guide treatment selection after a lung cancer diagnosis. Complementing its commercial tests, Biodesix Development Services provides test discovery, clinical-trial support, and companion diagnostics work for biopharmaceutical and life sciences partners.
Investors follow BDSX for its high-margin, recurring blood-test revenue model, its expansion beyond pulmonology into primary care, and its path toward sustained profitability. With gross margins near 80% and a growing pipeline spanning molecular residual disease (MRD) monitoring and digital diagnostics, Biodesix occupies a distinctive niche in early lung-cancer detection. I checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Price Action: 30 Days vs. Trailing Quarter
Over the last 30 days, BDSX has declined approximately 29%, falling from a close near $29.10 in late September to about $20.79 as of late October. The decline accelerated after the stock reached a 52-week high of $31.97 on September 28, with much of the selling concentrated in the final two weeks of the period.
The picture over the trailing quarter is more mixed. The stock began the period in the low $20s in late July, rallied roughly 45% into late September, and then gave back the entire advance. As a result, BDSX trades only modestly below where it stood roughly three months ago, underscoring how volatile the recent round-trip has been despite the sharp 30-day move.
Drivers Behind the 30-Day Move
The steep late-September advance into a 52-week high was supported by a steady stream of positive developments. Analysts raised price targets through September and October — including TD Cowen to $40, H.C. Wainwright to $38, and Roth MKM to $41 — citing large addressable markets, rapid test-volume growth, and margin momentum. Biodesix also announced a partnership with Vanderbilt University to develop a radiomics-based digital diagnostics platform for lung nodule risk assessment, and multiple real-world studies supporting Nodify Lung testing were presented at CHEST 2026.
The subsequent decline, however, appears tied to technical and sentiment factors rather than any single piece of negative news. After such a rapid climb, the stock became vulnerable to profit-taking, and the reversal gathered momentum as the shares broke below recent support levels. Broader volatility in small-cap healthcare and diagnostics names compounded the move. Notably, no major company-specific setback coincided with the pullback — analyst ratings remained Buy-equivalent, and management reaffirmed its full-year outlook. One thing that stands out here is how sentiment can shift quickly even when fundamentals stay steady.
Quarterly Performance and Growth Catalysts
The broader three-month narrative was driven by accelerating adoption of the company's lung diagnostics tests. In Q2 2026, Biodesix delivered $26.9 million in revenue, up 34% year over year, alongside an 82% gross margin. Primary care test volume grew sharply, and the company continued expanding its sales force while extending Nodify CDT into smaller lung nodules.
Progress on the MRD front and the digital diagnostics collaboration added to the growth story and helped fuel the rally into late September. Yet the same catalysts that powered the climb also set up the reversal: with the stock priced for continued execution, even routine profit-taking triggered an outsized correction. The result is a quarter defined by a sharp rally followed by an equally sharp giveback. From what I see, the fundamentals continue to support the longer-term case.
Key Factors to Watch Going Forward
Several factors will shape the stock's direction in the coming weeks. Biodesix reports third-quarter 2026 results on November 5, 2026, making revenue growth, gross margin, and any update to full-year guidance the near-term focus. Investors will also watch reimbursement and payer-coverage developments for the Nodify tests, as well as the company's research-and-development update expected around the November AMP meeting, which may shed light on MRD and pipeline programs.
Broader considerations include the pace of primary care adoption, sales-force productivity, progress toward sustainable adjusted EBITDA and free-cash-flow break-even, and the level of cash burn. As with any small-cap diagnostics name, sector rotation and risk sentiment can amplify price swings regardless of underlying fundamentals. I’m watching this closely as the next earnings release approaches.
Using AI Tools to Refine My View
I often use Tickeron’s AI Trading Bots to cross-check momentum signals and pattern recognition on names like BDSX. These automated strategies help me layer quantitative insights alongside the fundamental story, especially during periods of sharp volatility. Exploring the curated trending strategies can provide an extra data point when evaluating entry or exit levels.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BDSX's RSI Oscillator remains in oversold zone for 1 day
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +0.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDSX advanced for three days, in 201 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
BDSX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BDSX as a result. In 76 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for BDSX turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 45 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
BDSX moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BDSX crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BDSX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. BDSX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (24.532) is normal, around the industry mean (65.624). P/E Ratio (-6.858) is within average values for comparable stocks, (2.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.463) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 51 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties
Advertisement